Tuesday, 10 December 2024
signs of a good doctor
Monday, 9 December 2024
PRESCRIPTION (P-DRUG)
Hypertension Treatment
Country Differences:
- In the USA: ACE inhibitors (e.g., Lisinopril) are often the first choice for hypertension due to high prevalence of comorbid conditions like diabetes.
- In India: Calcium channel blockers (e.g., Amlodipine) are commonly preferred due to cost-effectiveness and better efficacy in salt-sensitive hypertension.
Doctor Differences:
- A cardiologist may prefer beta-blockers (e.g., Metoprolol) for a patient with coexisting heart disease.
- A general practitioner might choose a diuretic (e.g., Hydrochlorothiazide) due to affordability and simplicity.
Impact of Treatment Guidelines
Treatment guidelines provide evidence-based recommendations that directly influence P-drug selection.
Example 3: Hypertension
- USA (ACC/AHA Guidelines): Recommends ACE inhibitors (Lisinopril) or ARBs (Losartan) as first-line P-drugs for hypertension, especially in patients with diabetes or chronic kidney disease.
- UK (NICE Guidelines): Suggests calcium channel blockers (Amlodipine) as the first choice for hypertension in older adults or Black patients.
- India: Diuretics (Hydrochlorothiazide) are often selected due to affordability and inclusion in national guidelines.
Understanding Clinical Guidelines
Example 1: Hypertension Treatment
- Doctor A: Interprets the American Heart Association (AHA) guidelines and emphasizes ACE inhibitors (Lisinopril) for hypertension in diabetic patients due to their protective renal effects.
- Doctor B: Focuses on the same guidelines but prefers ARBs (Losartan) because they are equally effective and have a lower risk of cough as a side effect.
"All diseases need not to be treated with a drug."
Example 1: Hypertension
- Non-drug approach: Lifestyle modifications such as regular exercise, low-sodium diet, weight loss, and stress reduction can be effective in controlling mild hypertension.
- Rationale: Drugs may not be immediately necessary, especially in borderline cases.
PDL MR COMMUNICATION
https://iris.who.int/bitstream/handle/10665/69177/WHO_EDM_PAR_2004.3_eng.pdf?sequence=1
Ethical criteria for medicinal drug promotion
https://iris.who.int/bitstream/handle/10665/38125/924154239X_eng.pdf?sequence=1&isAllowed=y
INDIAN MEDICAL COUNCIL (Professional Conduct, Etiquette and Ethics) Regulations, 2002
(AMENDED UPTO 8th OCTOBER 2016)
https://www.nmc.org.in/wp-content/uploads/2017/10/Ethics-Regulations-2002.pdf
https://www.nmc.org.in/documents/e_Gazette_Amendments/Ethics%20-%2010.12.2009.pdf
Code of Medical Ethics Regulations, 2002
https://www.nmc.org.in/rules-regulations/code-of-medical-ethics-regulations-2002/
LOK SABHA UNSTARRED QUESTION NO.4422 TO BE ANSWERED ON 19TH JULY, 2019 UNETHICAL PRACTICES 4422. SHRI SYED IMTIAZ JALEEL:
https://sansad.in/getFile/loksabhaquestions/annex/171/AU4422.pdf?source=pqals
Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 (Published in Part III, Section 4 of the Gazette of India, dated 6th April, 2002) MEDICAL COUNCIL OF INDIA NOTIFICATION New Delhi, dated 11th March, 2002
https://wbconsumers.gov.in/writereaddata/ACT%20&%20RULES/Relevant%20Act%20&%20Rules/Code%20of%20Medical%20Ethics%20Regulations.pdf
Shastri Bhawan, New Delhi March, 2024 Subject: Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 — reg. Sir / Madam,
नाहं कालस्य, अहमेव कालम|
नाहं कालस्य, अहमेव कालम|
MAI AHAM NAHI HU
MAI AATMA HU
https://acharyaprashant.org/en/articles/naaham-kaalasya-ahamev-kaalam-1_593683c
Sunday, 8 December 2024
Bhagavad Gita (Chapter – 4, Verse – 7)
Thursday, 5 December 2024
ETHICAL
censure